Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study / E. Iannitto, S. Ferrero, C. Bommier, D. Drandi, M. Ferrante, K. Bouabdallah, S. Carras, G. Gini, V. Camus, S. Mancuso, L. Marcheselli, A. Ferrari, M. Merli, B. Tessoulin, C. Stelitano, K. Beldjord, G. Roti, F. Jardin, B. Castagnari, F. Palombi, L. Baseggio, A. Traverse-Glehen, C. Tripodo, A.M. Liberati, M. Parolini, S. Usai, C. Patti, M. Federico, M. Musso, M. Ladetto, E. Zucca, C. Thieblemont. - In: HAEMATOLOGICA. - ISSN 1592-8721. - 109:7(2024), pp. 2297-2302. [10.3324/haematol.2023.284109]
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
C. Tripodo;
2024
| File | Dimensione | Formato | |
|---|---|---|---|
|
11509-Article Text-83751-1-10-20240314.pdf
accesso aperto
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
3.3 MB
Formato
Adobe PDF
|
3.3 MB | Adobe PDF | Visualizza/Apri |
|
11509-Article Text-83751-2-10-20240626.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
4.01 MB
Formato
Adobe PDF
|
4.01 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
